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Abstract
Purpose We demonstrated that Hsa-miR-567 expression is
significantly downregulated in poor prognosis breast can-
cer, compared to better prognosis breast cancer, having a
role in the control of cell proliferation and migration by
regulating KPNA4 gene.
Methods and results In this study, based on our previously
published in silico results, we proved both in vitro (cell line
studies) and ex vivo (clinical studies), that Hsa-miR-567
expression is significantly downregulated in breast cancer
with poor prognosis when compared to breast cancer with
better prognosis. More intriguingly, we demonstrated that
the ectopic expression of Hsa-miR-567 in poor prognosis
breast cancer cell line strongly inhibits in vitro cell pro-
liferation and migration. Furthermore, we showed in vivo
that breast cancer cells, stably expressing Hsa-miR-567,
xenografted in mouse, reduce tumor growth ability. Con-
sistently, we found that karyopherin 4 (KPNA4), predicted
target gene of Hsa-miR-567 as identified by our in silico
analysis, is upregulated in highly aggressive MDA-MB-
231 breast cancer cell line and patient tissues with poor
prognosis with respect to good prognosis.
Conclusions Our results suggest a potential role of Hsa-
miR-567 as a novel prognostic biomarker for BC and as
regulator of KPNA4.
Keywords MicroRNA/miRNA  Breast cancer 
Prognosis  Biomarker  Proliferation
Introduction
Breast cancer (BC) is one of the most common cancers
worldwide and the most frequent women tumor (25% of all
new cases diagnosed in 2015) [14, 25]. Although the cur-
rent histological and biological indexes (i.e., tubule for-
mation, nuclear polymorphism, mitotic count,…) [2, 10]
have shown association with clinical outcome of BC
patients, these indexes are limited in their ability to make
prognosis for all BC patients.
With the advent of microarray and the sequencing of the
human genome, transcriptomic analysis has significantly
improved the knowledge of the biological mechanisms
leading to malignant transformation of BC, providing
better molecular ‘portrait’ of BC and allowing the identi-
fication of new BC prognostic and predictive tools.
Several gene profiles have been proposed for the clas-
sification of BC [i.e., the 105-gene profile by Perou [24],
70-gene profile in Mammaprint by van ‘t Veer [29],
21-gene profile in Oncotype by Paik [22], 97 gene profile
by Sotiriou [26], 18 gene profile, and 6 gene profile by
Ivshina [13]]. Notwithstanding these gene profiles have
few genes in common, they have consistently shown that
BC patients can be classified into two groups with different
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prognosis, namely grade 1 (G1)-like and grade 3 (G3)-like
groups, representing the two different prognostic groups
defined by histological analysis as G1 and G3 [13].
MicroRNAs (miRNAs or miRs) are small, highly con-
served, non-coding RNAs that regulate gene expression of
target mRNAs. They are widely involved in several physi-
ologic processes, but they are also responsible for patho-
logical conditions, such as carcinogenesis and cancer
development [11]. miRNA profiles obtained by ‘omics’-
based technology can classify human cancers even better
than mRNA profile [19, 27]. Moreover, miRNAs are
emerging as easy accessible cancer disease biomarkers, as
they have been found stably present in human biofluids (i.e.,
blood, saliva, urine…) [3, 4]. These features make miRNAs
interesting, non-invasive, and cost affordable biomarkers for
clinical diagnosis, prognosis, and therapy of BC.
By combining gene expression profile, copy number
alterations, andmiRNAexpression profiles as available from
published datasets of BC human tissue samples, we have
recently identified in silico, a 4-miRNA signature (Hsa-miR-
567, Hsa-miR-139-5p, Hsa-miR-320d, Hsa-Let-7c) and a
4-target mRNA signature (KPNA4, H2AFV, FOXM1,
DDX19A) that are able to accurately classify BCpatients into
G1-like and G3-like groups, thus improving BC grade defi-
nition and confirming the existence of only two prognostic
groups [5]. Our signature was the first one, to our knowledge,
consisting of miRNAs with these prognostic properties in
BC. In particular, it was the first time that Hsa-miR-567
(miR-567) was found significantly downregulated in BC.
Following our preliminary in silico results, the present study
aims at elucidating the role ofmiR-567 for the prognosis of BC
and as regulator of karyopherin 4 (KPNA4), and to investigate
the effects caused by a dysregulation ofmiR-567. Specific aims
of our study are to assess the following, by experimental stud-
ies: (1) if the expression level of miR-567 is significantly
downregulated in BC with poor prognosis when compared to
BC with good prognosis (and, consistently, if the expression
level of KPNA4 is significantly upregulated), and (2) miR-567
modulation effects on BC tumor cell proliferation and migra-
tion. To reinforce the evidences of a crucial role in BC of
KPNA4 and miR-567, we implemented a classification algo-
rithm and evaluated the performances of proposed biomarkers
in the classificationofG1andG3BCand in the re-classification




For in vitro studies, we used two human BC epithelial cell
lines: G1-like MCF7 and G3-like MDA-MB-231 cells [12]
(ICLC-Biologic Bank and Cell Factory, Italy). We have
chosen MCF7 and MDA-MB-231 cell lines for their ability
to form moderately well-differentiated infiltrating ductal
carcinomas (grade I) and poorly differentiated adenocar-
cinoma (grade III), respectively, when xenografted in
mouse [https://www.lgcstandards-atcc.org/Products/All/
HTB-26.aspx#characteristics] [12, 31]. Following the
manufacturer’s recommendation, we maintained the cell
lines within a humidified atmosphere containing 5% CO2 at
37 C in DMEM cell culture medium (Gibco, Life Tech-
nologies), with 10% fetal bovine serum (FBS) (Lonza,
Euroclone). Dulbecco Phosphate-Buffered Saline (D-PBS),
trypsin, and all the media additives (penicillin, strepto-
mycin, D-glutamate, non-essential amino acids) were
obtained by Lonza (Euroclone).
BC human tissue samples
We used 13 G1 and 13 G3 snap-frozen human BC tissues,
diagnosed histopathologically at ‘‘Salvatore Maugeri’’
Foundation, at the Histopathology Service, from 2009 to
2015. G1 and G3 grade definition was established
according to the Scarff-Bloom-Richardson (SBR) grading
system [1].Tissue samples were immediately stored as
frozen aliquots in the ‘‘Bruno Boerci’’ Institutional Onco-
logic Bio-bank after surgery until further use, according to
the guidelines of European Bio-banking and Biomolecular
Resource.
BC animals and animal tissue samples
Fourteen adult female nude mice (athymic nude-Foxn1 Nu/
Nu), 7–8 weeks old, were used for the in vivo experiment,
and xenografted to model BC.
During in vivo study, mice were maintained on a 12-h
light–dark cycle in cages of five animals with water and
food ad libitum.
For ex vivo studies, at the end of the experiments, mice
were sacrificed by cervical dislocation after sedation and
five explanted tumors, from five mice were immediately
stored in liquid nitrogen for further use.
RNA isolation and reverse transcription (in vitro
and ex vivo studies)
Total RNA was isolated using TRIzol reagent (Life Tech-
nologies) following the manufacturer’s recommendations.
Two micrograms of total RNA were reverse transcribed
using miRCURY LNA Universal RT microRNA PCR
(Exiqon, Euroclone) to obtain poly-A-tailed miRNA
cDNA. U6 spike-in RNA was added in the reaction as an
internal control for the reverse transcription and real-time
PCR (RT-PCR) amplification.
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Two micrograms of total RNA, treated with DNAse I
(Euroclone, Italy), were reverse transcribed using oligo dT
primers in combination with SuperScript II Reverse Tran-
scriptase (Life Technologies) in order to obtain total cDNA
for gene expression analysis, following the manufacturer’s
protocol.
RT-PCR for analysis of miR-567 and KPNA4
expression levels
miR-567 and KPNA4 expression levels were analyzed on
BC cell lines and human samples. RT-PCR was performed
using SybrSelect Master Mix (Applied Biosystem, Life
Technologies), in an Eco RT-PCR (Illumina).
Primer sequences for miR-567 expression analysis have
been purchased from Exiqon (Euroclone, Italy) (Accession
No. MI0003573). The level of expression of miR-567 was
normalized on the level of U6 control gene.
Primer sequences for gene expression analysis are: for
KPNA4 (ID3840) Fw: 50- CAGGAGATTCTTCCAGCC
CTTTGTGT-30, Rw: 50- ATTACCATCTGTATTTGTT
CATTGCCAGCATC-30. For ribosomal protein S14
(RPS14) (ID6208) Fw: 50- GGCAGACCGAGATGAATC
CTCA-30, Rw: 50- CAGGTCCAGGGGTCTTGGTCC-30.
RPS14 was used as internal control for RT-PCR quantifi-
cation.
The relative expression of miR-567 and KPNA4 was
calculated for both G3 and G1 cell lines and human sam-
ples with the 2ðDDCTÞ method [17]. Experiments were
performed three times in triplicate (n = 9). A t test was
calculated among G3 and G1 cell lines and human samples.
miR-567 stable transfectant generation in G3-like
cell line: miR-567 and KPNA4 analyses
MDA-MB-231 cells stably overexpressing miR-567
(MDA-miR) or scramble sequence (MDA-Scr) (for the
scramble sequence see [18]) were obtained by seeding
50,000 cells in 24-well plate (Euroclone) and transfecting
them with 500 ng of pCMV-miR567-GFP (Origene,
Nockville, MD) or 100 nM scramble, respectively, in the
presence of Lipofectamine 2000 reagent (Invitrogen), fol-
lowing the manufacturer’s suggestions. After 48 h, the
medium was changed, and G418/Neomycin (Euroclone)
500 ug/ml was added. The whole population was main-
tained for 3 weeks in selection (3 passages/week) to obtain
a stable transfectant cell line.
After 3 weeks, to assess the efficiency of the stable cell
transfection, we evaluated the expression levels of miR-567
and KPNA4 in the whole population of MDA-miR versus
MDA-Scr by RT-PCR, using the same protocol described
above.
miR-567 stable transfectant generation in G3 cell
line: Kpna4 protein analysis
Total lysates were obtained by lysing 1 9 106 of MDA-ctr
cells and MDA-miR cells 30 min in RIPA lysis buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 2% SDS,
0.15% deoxycholic acid, 1 mM EDTA, pH 8. 0) containing
complete protease inhibitor (Roche, Monza, Italy), leu-
peptin and aprotinin inhibitors (Sigma Aldrich). Lysates
were spun at 12,0009g for 30 min and the supernatants
collected. Estimation of protein concentration was per-
formed with 660 nm Protein assay (Pierce, Thermo Sci-
entific, France) on a Fluostar Omega plate reader (BMG
Labtech, Germany).
Twenty micrograms of total proteins were loaded on 8.5,
10, or 12% SDS–PAGE and run for 1.5 h at 30 mA/gel.
Proteins were transferred onto nitrocellulose membrane
(Sigma Aldrich) at 250 mA for 4 h. Membranes were
blocked in TBS-0.1% Tween-20 containing 5% skim milk
powder (Euroclone, Italy), and incubated with primary
antibodies: rabbit polyclonal anti-beta Actin (OriGene,
MD, USA), anti-Histone H3 (Origene, MD, USA), or anti-
Tubulin (sc-5286, Santa Cruz Biotechnologies) used 1:000;
rabbit polyclonal anti-Kpna4 (Thermo Fisher Scientific, IL,
USA) diluted 1:750. After incubation with goat anti-rabbit
HRP secondary antibody (sc-2004, Santa Cruz Biotech-
nologies) or goat anti-mouse HRP (sc-2005, Santa Cruz
Biotechnologies) at 1:5000, membranes were developed
using the SuperSignal West Pico Chemiluminescent Sub-
strate (ThermoScientific, France) on Amersham Hyperfilm
MP (Ge Helthcare, Italy).
To assess the stable transfection, we evaluated the
expression levels of Kpna4 protein in MDA-ctr and MDA-
miR by Western Blot analysis, normalizing the Kpna4
protein to histone H3. The blots of both proteins were
quantified by ImageJ software (http://imagej.nih.gov/ij/).
Experiments were performed two times in triplicate
(n = 6). A t test was calculated among MDA-miR and
MDA-ctr.
Luciferase assay
To assess if KPNA4 is a direct target of miR-567, pMiR-
target vector, containing the 30UTR of human KPNA4
sequence (Origene, Nashville), was transfected with lipo-
fectamine 3000 (Invitrogen) in MDA-MB-231 cells,
according to the manufacturer’s suggestion, in combination
with 100 nM mimic miR-567 or 100 nM scramble miR
sequence. After 24 h, Luciferase activity was measured in
GloMax-Multi Detection System (Promega, Madison, WI,
USA) and normalized on total protein content. Protein
quantification has been performed with Bradford method
(Promega).
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In vitro study of tumor cell proliferation
Tumor cell viability was assessed by following the growth of
50,000MDA-ctr cells or MDA-miR, seeded in 24-multiwell
plate.Attime0,24,48,72 hfromseeding,thecellsweregently
washedwithPBS,trypsinizedandcountwithTrypanBlue.
A graphic representation of the results was obtained by
plotting the number of the total cells at each time point.
Experiments were performed three times in triplicate
(n = 9). A t test was calculated among MDA-miR and
MDA-ctr.
In vitro study of tumor cell migration
To study directional cell migration, we performed a
wound-healing study. The MDA-ctr and MDA-miR cells
were seeded at confluence (about 1,50,000/well) in 24-well
plate (Euroclone). After 6 h, necessary for adhesion, a
scratch was performed in the middle of each well [16].
After washing the cells, new medium was added, and
pictures of each well were taken every 24 h. The effect on
cell migration was quantified by ImageJ software. Exper-
iments were performed three times in triplicate (n = 9). A
t test was calculated among MDA-miR and MDA-ctr.
In vivo study of tumor growth
To engineer cells, a pCCL.PGK.luciferase.WPRE (PLW)
lentivector was in vitro used (kindly provided by Dr.
S. Rivella). The construct permitted the expression of
luciferase reporter gene under control of phosphoglycerate
kinase 1 (PGK) promoter.
PLW lentiviral particles were produced by transient
transfection into 293 T cells using calcium phosphate
precipitation, as described elsewhere [6]. The transfection
medium (IMDM, Euroclone, plus 10% FBS, Cellgrow) was
replaced 16 h later. The conditioned medium, containing
the viral particles, was collected 24 and 48 h after the
medium replacement, filtered through cellulose acetate
filter 0.2 lm, and frozen at -80 C until further use. The
vector titer was determined by serial dilution on HeLa cells
through Real-Time PCR.
MDA-ctr or MDA-miR cells were plated and infected
with PLW particles with a MOI of five in the presence of
Polybrene (8 ug/ml), generating MDA-ctr ? Luc (MDA-
Luc) or MDA-miR ? Luc (MDA-miR-Luc). Cells were
washed 16 h later in order to remove all viral particles.
Five millions of cells either from MDA-Luc or MDA-
miR-Luc were resuspended in 40 ll of sterile PBS and
injected orthotopically in the fourth mammary gland of the
animals. Briefly, mice were anesthetized with Zole-
til ? Xilor 2% (40 and 8 mg/kg, respectively) and a 4-mm
incision was performed on the skin, in the proximity of the
mammary gland. The needle of the syringe was inserted to
the mammary gland, and cells were delivered. Following,
skin incision was sutured with a 6/0 silk suture thread and
mice were followed until complete recovery.
To analyze tumor growth, bioluminescence imaging was
performed at different time points. After anesthetization,
the 14 mice were injected with 50 mg/kg of luciferin
(Beetle Luciferin Potassium Salt, Promega), and after
biodistribution, bioluminescence signal was acquired.
All acquisitions were carried out with IVIS SPEC-
TRUM/CT system (PerkinElmer). Images were analyzed
and normalized, using the Living Image Software. Data
were expressed as average radiance (photons/seconds/cm2/
steradian). The scale and the average radiance used for the
images took into account the difference in luciferase
activity for the two cell lines.
Dimension of all 14 tumors was measured by caliper on
animals at different time points. The tumor volumes were
calculated by multiplying the three dimensions of the
tumor measured by caliper.
In order to assess if the upregulation of miR567 was main-
tained during the in vivo study, five explanted tumors from five
xenografted animals, generated by MDA-Luc or MDA-miR-
Luc, were collected, weighted, and analyzed for RNA,mRNA,
and protein content by RT-PCR or Western blot.
Bioinformatic classification approach
In silico validation analysis using KPNA4 and miR-567 was
performed from an independent dataset of GEO database:
GSE22220. This dataset contains mRNA and miRNA
expression profiles from the same patients: 41 G1 BC, 81
G2 BC, and 61 G3 BC samples.
In order to evaluate the performances of the two pro-
posed biomarkers, we developed a Support Vector
Machine (SVM) classification model using the R-package:
e1071 [20]. AUC was estimated by cross-validation
method (k-fold cross-validation, k = 10).
We optimized inference AUC over a space of given SVM
feasible learning parameters: cost ¼ 10ð1:2Þ , gamma =
c(0.2,1,2); kernel type = RADIAL (see e1071 documentation
at [20] (https://CRAN.R-project.org/package=e1071]). This
approach allowed us to find the best SVM learning parameters
for each data type over the same space of values.
We implemented a Monte Carlo Cross-Validation
method. It randomly selected some fractions of GEO data
(60% of original dataset) to form the training set, and then
assigned the rest of the points to the testing set (40% of
original dataset). This process was then repeated multiple
times (ten bootstraps), generating randomly new training
and test partitions each time. For each bootstrap, we
obtained an AUC value.
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In order to avoid problems of unbalanced classes, we ran-
domly selected classes with the same number of BC sample in
both the training and testing dataset for each evaluation.
The classifier was tested for the following reasons: (1) to
distinguish histological G1 and G3 BC patients using miR-
567 andKPNA4 expression profiles and (2) to re-classify G2
using miR-567 and KPNA4. For this purpose, the machine
learning algorithm based on SVM was used to classify G2
BC patients in G1 or G3 class. The results of testing G2
samples were classified as G1 or G3 (namely G1* and G3*).
These classes G1* and G3* were used to train SVM again
and to test to the different G1 and G3 BC datasets.
Results
miR-567 is significantly downregulated and its target
KPNA4 is significantly upregulated in G3 versus G1
BC cell lines
To validate that the expression level of miR-567 is down-
regulated and KPNA4 mRNA is upregulated in G3 versus
G1 BC, we performed a RT-PCR in MDA-MB-231 and
MCF7 cell lines. As shown in Fig. 1a, miR-567 expression
in MDA-MB-231 is significantly downregulated compared
to MCF7 cell line. As shown in Fig. 1b, the relative
expression of KPNA4 mRNA is significantly higher in
MDA-MB-231 versus MCF7 cell line.
miR-567 is significantly downregulated and KPNA4
is significantly upregulated in G3-like versus G1-like
BC human tissues
To validate that the expression level of miR-567 is down-
regulated in G3 versus G1 BC human tissue samples and
that expression level of KPNA4 is lower in G1 samples
versus G3 samples, we performed a RT-PCR in 13 G3
versus 13 G1 samples. In Fig. 2a, we showed that the
expression level of miR-567 is lower in G3 human tissue
samples versus G1 samples, with an average of
5.95 9 10-7 ± 7.40 9 10-7 in G1 and of
6.23 9 10-7 ± 1.05 9 10-7 in G3 samples, respectively.
In Fig. 2b, we showed that the expression level of KPNA4
is lower in G1 samples versus G3 samples, with an average
of 0.185 ± 0.218 in G3 and of 0.093 ± 0.129 in G1
samples, respectively.
miR-567 modulation has effects on BC cell
proliferation and migration
Since miR-567 is downregulated in poor prognosis G3
cells, to evaluate the effect of miR-567 upregulation on cell
behavior, we generated a stable transfectant, overexpress-
ing miR-567 in MDA-MB-231 cell line. Figure 3a shows
that the vector transfection significantly increased miR-567
expression up to 32.15 ± 8.32 fold in MDA-miR versus
MDA-ctr cells.
To evaluate the effect of miR-567 overexpression on
KPNA4 target gene levels, we analyzed both the mRNA
levels and the protein levels. As shown in Fig. 3b, miR-567
stable upregulation decreased KPNA4 mRNA expression to
0.57 ± 0.13 fold in MDA-miR versus MDA-ctr cells by
RT-PCR analysis.
Western blot analysis revealed that Kpna4 protein is also
reduced in MDA-miR compared to MDA-ctr cells (Fig. 3c)
to 76.34 ± 18.48 (ImageJ quantification, Fig. 3d). Luci-
ferase assay confirmed that KPNA4 gene is a direct target
of miR-567 (Fig. 3e).
Fig. 1 a RT-PCR relative expression of miR-567 normalized on U6
housekeeping gene, in MCF7 (in white) and MDA-MB-231 (in gray)
cell line, respectively. All data are presented as mean ± SD of
experiments for each bar (***t test p value = 4.5 9 10-5, n = 9).
b RT-PCR relative expression of KPNA4 gene normalized on RPS14
housekeeping gene, in MCF7 (in white) and MDA-MB-231 (in gray)
cell line respectively. All data are presented as mean ± SD of
experiments for each bar (**t test p value = 0.0048, n = 9)
Breast Cancer Res Treat (2017) 161:605–616 609
123
Upregulation of miR-567 decreases tumor cell
proliferation
MDA-miR and the parental MDA-ctr cell lines were tested
in growth curve assay (Fig. 4). The overexpression of miR-
567 decreased the proliferation of MDA-miR in respect to
MDA-ctr cells (Fig. 4a). The percentage of apoptotic cells
was not affected by the overexpression of miR-567 (data
not shown).
Upregulation of miR-567 decreases cell migration
To test the influence of miR-567 overexpression on ability
migration of BC cells, we performed wound-healing assay.
MDA-miR showed a lower ability to heal the wound in the
MDA-miR cell culture well compared to MDA-Scr cells
(Fig. 4b). The difference in the wound area between the
two cell lines, quantified by ImageJ, was statistically sig-
nificant at time 24, 48, and 72 h (Fig. 4c).
Upregulation of miR-567 decreases in vivo tumor
growth
To test if miR-567 affects the proliferation of BC tumor
cells in vivo, we analyzed the behavior of MDA-miR and
MDA-ctr implanted in mouse mammary gland. To follow
the growth of the tumors, both MDA-miR and MDA-ctr
cell lines were engineered in vitro by infection with the
PLW construct, producing a detectable signal from luci-
ferase activity. The efficiency of infection was about 90%
(data not shown) and the MDA-miR cells showed a higher
level of signal compared to MDA-ctr cells (ratio of MDA-
miR/MDA-ctr = 5.7 fold)—this difference is only due to
the differential amount of vector copies integrated in the
two cell models (2.125:1 in MDA-miR versus MDA-ctr,
respectively) and not to a difference in cell behavior.
As shown in Fig. 5a, a different tumor growing rate was
observed by optical imaging: the overexpression of miR-
567 stable construct caused a delay in the growth of the
tumors if compared to the growth of MDA-ctr generated
tumors (image scale took into account the difference in
luciferase constitutive activity of the two cell lines).
The quantification of bioluminescent signal by ROIs
showed a very different rate of tumor growth, as demon-
strated by the significant t test (Fig. 5b).
This result was confirmed by evaluation of tumor volumes,
as recorded by caliper at each time point of signal acquisition,
and of tumor weight at the end of experiment, showing a
smaller tumor (both in volume and weight) formed by MDA-
miR compared to MDA-ctr cells (Fig. 5c–d, respectively).
On the explanted tumors, as expected, miR-567
expression was maintained upregulated in MDA-miR
compared to MDA-ctr cells (fold change expression was in
mouse 1: 3.03 ± 1.20; in mouse 2 = 2.52 ± 0.87; in
mouse 3 = 3.51 ± 1.65; in mouse 4 = 3.22 ± 0.77,
respectively) (Fig. 6a). One sample (mouse 5) showed an
outlier expression of miR-567, with a relative expression of
366.67 ± 2.34 fold of increase.
Consistently, on the explanted tumors, KPNA4 expres-
sion was found downregulated in MDA-miR compared to
MDA-ctr cells (fold change expression of KPNA4 was in
mouse 1: 0.01 ± 0.01; in mouse 2 = 0.35 ± 0.03; in
mouse 3 = 0.44 ± 0.14; in mouse 4 = 0.33 ± 0.01; in
mouse 5 = 0.90 ± 0.09, respectively) (Fig. 6b).
Fig. 2 a Relative expression of miR-567 normalized on U6 in 13 G1
(in white) versus 13 G3 (in gray) BC. All data are presented as
mean ± SD of experiments for each point. Black bars represent the
average of each group. (*t test p value = 0.0223, n = 13). b Relative
expression of KPNA4 normalized on RPS14 in 13 G1 (in white)
versus 13 G3 (in gray) BC. All data are presented as mean ± SD of
experiments for each point. Black bars represent the average of each
group (*t test p value = 0.047, n = 13)
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Bioinformatic approach to evaluate the performance
of miR-567 and KPNA4 in G1–G3 classification
Figure 7 shows heat maps of classification performances for
G1 versus G3 BC samples, and for the re-classification G2
samples, training on G1*–G3*and testing on G1–G3 for each
bootstrap. Mean AUC values showed a good performance of
0.78 [(CI 95%) 0.71–0.84] and 0.76 [(CI 95%) 0.74–0.77],
respectively. The best performance in G1 versus G3 was
obtained in the seventh bootstrap getting an AUC value 0.95.
In the re-classification the best performance was 0.8.
Discussion
In this study, we explored the role ofmiR-567 in BC. Our study
was based on the results coming from three BC experimental
models: cellular model, mouse model, and human samples.
We investigated the role of miR-567 in G3 versus G1
BC cell lines, and miR-567 was found clearly differentially
expressed (Fig. 1a). To better clarify the role that the
downregulation of miR-567 has in higher-grade tumor
behavior and the genes that are potentially target of miR-
567 regulation, we overexpressed miR-567 construct in
MDA-MB-231 cells (Fig. 3a–d). miR-567 upregulation has
a drastic effect on cell growth, as revealed by the decrease
in cell proliferation (Fig. 4a). In addition, its upregulation
strongly affects the migration capability of the cells, as
revealed by wound-healing assay (Fig. 4b–c).
In our previous publication [5] by in silico analyses, we
had suggested KPNA4 as a possible target of miR-567.
Several members of the KPN family are activated in solid
tumors (i.e., [9]) and in particular in BC [21]. Kpna4, a
nuclear protein with a role in nucleocytoplasmic traffick-
ing, could be involved in signal-transduction pathways and
Fig. 3 a Relative expression of miR-567 normalized on U6 in MDA-
ctr cells (in white) versus MDA-miR (in gray). All data are presented
as mean ± SD of experiments for each bar (*t test p value = 0.02,
n = 9). b Relative expression of KPNA4 normalized on RPS14 in
MDA-ctr cells (in white) versus MDA-miR (in gray) cell lines,
respectively. All data are presented as mean ± SD of experiments for
each bar (*t test p value = 0.012, n = 9). c Western Blot of KPNA4
protein and Histone H3, used as normalizing protein. d Western Blot
quantification of KPNA4 protein normalized on Histone H3 in MDA-
ctr (in white) and MDA-miR (in gray) cells. All data are presented by
mean ± SD of experiments for each bar (*t test p value = 0.05,
n = 6). e Luciferase assay results are depicted in the graph. The
relative luminescence activity (RLU) has been normalized on total
protein content for each sample. CTR: untreated MDA-MB-231;
30UTR: MDA-MB-231 transfected with pMirTarget vector containing
30UTR of hKPNA4 sequence; 30UTR ? miRNA: MDA-MB-231
transfected with pMirTarget vector containing 30UTR of hKPNA4
sequence, in combination with 100 nM mimic miR-567 oligonu-
cleotide; 30UTR ? scramble: MDA-MB-231 transfected with
pMirTarget vector containing 30UTR of hKPNA4 sequence, in
combination with 100 nM scramble oligonucleotide. All data are
presented as mean ± SD of experiments for each point (**t test
p value = 0.0013, n = 3)
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cell-cycle control [33, 34]. In Fig. 1b, we showed that
MDA-MB-231 cell line has an increased level of KPNA4
consistently with to the downregulation of miR-567
expression. miR-567 upregulation in MDA-MB-231 cell
line decreases the expression level of KPNA4 both as
mRNA and protein in a statistically significant way
(Fig. 3c–d), and luciferase assay confirms a direct inter-
action between miR-567 and KPNA4 30 UTR (Fig. 3e).
Looking at the results from ex vivo experiments, KPNA4
expression levels measured by RT-PCR in G3 versus G1
BC human samples revealed that this target gene is over-
expressed in G3 (Fig. 2b), as expected [5]. These results
suggest that in BC, KPNA4 upregulation, as effect of miR-
567 downregulation, could contribute to the aggressive
phenotype of G3 BC tumors.
A similar anti-proliferative effect obtained by miR-567-
transfected cell analysis in in vitro study was obtained
in vivo. We analyzed the tumors generated by MDA-miR
compared to those obtained by MDA-ctr. We observed that
MDA-miR-generated tumors showed a lower growth rate
that those obtained by MDA-ctr cells (Fig. 5). These data
confirm that miR-567 is also able in vivo to control the
growth rate of highly aggressive BC cells.
The clinical significance of miR-567 in BC has not been
evaluated yet. In the present study, miR-567 downregula-
tion has been detected in poor prognosis G3 human sam-
ples compared to better prognosis G1 human samples,
suggesting a correlation between miR-567 expression and
prognosis (Fig. 2). The same results have been obtained for
KPNA4 expression level analysis in G3 versus G1 BC
samples (Fig. 2). Also, in silico analysis showed the good
performances of miR-567 and KPNA4 to distinguish G1
and G3, and in the re-classification of G2, using an inde-
pendent dataset (Fig. 7).
No publication associates miR-567 expression levels to
BC, although two papers showed, in silico, a correlation
between miR-567 expression and colon cancer (CRC)
[8, 30]. In CRC, miR-567 has been proposed as a controller
Fig. 4 a Growth curve of MDA-Scr (dashed black line) and MDA-
miR (solid gray line) cell lines. All data are presented as mean ± SD
of experiments for each point at each time point (***t test
p value = 1.28 9 10-7, n = 27). b Behavior of MDA-Scr and
MDA-miR cells in wound-healing test. c ImageJ quantification of the
effect of the miR-567 overexpression in MDA-miR compared to
MDA-Scr cells, on wound-healing assay. All data are presented as
mean ± SD of experiments for each bar at each time point
(**p value\ 0.01, ***t test p value\ 0.001, n = 3, respectively)
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of SMAD4 pathway. SMAD4, a major component of the
transforming growth factor b (TGF-b) signaling pathway,
has been found activated in metastatic BC [32]. TGF-b
pathway is crucial for the invasion and migration of BC
cell in surrounding tissue [23], and it is upregulated in 81%
of the patients with aggressive cancer [7, 15]. It is possible
that miR-567 is modulated by TGF-b pathway also in BC
and, in turn, regulates some components of this pathway, as
SMAD family members.
The higher expression of TGF-b is able to modulate a
component of KPN karyopherin family, namely KPNA2,
involved in the control of keratinocyte proliferation and
differentiation [29]. We can hypothesize that in a normal
cell, low levels of TGF-b allow the expression of miR-567,
which in turn decrease KPN family members, regulating
the cell growth. In highly aggressive BC, TGF-b is
increased, causing possibly the strict decrease in miR-567
expression and consequently the upregulation of KPNA4,
Fig. 5 a Bioluminescence imaging of a representative mouse
injected with MDA-ctr (control) cells or with MDA-miR cells. All
the images are scaled with the same color bar. b Graphical
representation of average of Luciferase activity acquired for each of
the tumor formed by MDA-ctr (ctr) and MDA-miR (miR) cell lines,
respectively, at different time points (day 3, 7, 10, 17, 22). Data are
presented as average radiance (photons/s/cm2/steradian). All the bars
are mean ± SEM of experiments for each cell line at each time point
(**t test p value day 7 = 0.008; *t test p value day 17 = 0.015;**
t test p value day 22 = 0.007, n = 14). c Graphical representation of
average of volume for each of the tumor formed by MDA-ctr (ctr) and
MDA-miR (miR) cell lines, respectively, at each time point (day 3 7,
10, 17, 22). All the bars are mean ± SEM of experiments for each
cell line at each time point (*t test p value day 3 = 0.025; **t test
p value day 7 = 0.010; **t test p value day 17 = 0.006; **t test
p value day 22 = 0.002, n = 14). d Representative image of the
difference in the volume of explanted tumors, generated by MDA-ctr
(left) and MDA-miR (right) cells, respectively
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increasing cell proliferation. This hypothesis is depicted in
Fig. 8. However, further experiments are needed to confirm
it.
In this study, we could propose miR-567 as a therapeutic
tool: the use of miR-567 mimic oligonucleotide could be
effective in modulating BC growth through targeting of
KPN family members. The balance of miR-567 expression
by mimic oligonucleotide administration could become a
possible therapeutic strategy for poor prognosis BC.
Several attempts have been made to use miRNAs as pos-
sible therapeutic tools [3], but further efforts are needed to
achieve this purpose.
In conclusion, we found a high increase of miR-567 in
low-risk G1 versus G3 cell lines and even in the corre-
sponding explanted tumors from xenografted mice. A sig-
nificant difference has been also found between G1 and G3
human BC tissue samples. Our findings suggest that miR-
567 could act as an oncogene, as its downregulation
Fig. 6 a Relative expression (log scale) of miR-567 normalized on
U6 on five explanted tumors formed by MDA-miR ? luc (in gray) or
MDA-ctr ? luc (in white) cells, respectively. All data are presented
as mean ± SD of experiments for each tumor (1–5) (t test
*p value\ 0.05; **p value\ 0.01, n = 9). b) Relative expression
of KPNA4 normalized on RPS14 on five explanted tumors (1–5)
formed by MDA-miR ? luc (in gray) or MDA-ctr ? luc (in white)
cells, respectively. All data are presented as mean ± SD of exper-
iments for each tumor (t test **p value\ 0.05; ***p value\ 0.001,
n = 9)
Fig. 7 Heat maps depicting the
predictive performance of
KPNA4 and miR-567
classification for G1 versus G3
and for G1 versus G3, training
on G1*–G3*, and testing on
G1–G3 for each bootstrap b
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decreases cell proliferation in poor prognosis BC,
increasing expression level of KPNA4. miR-567 might
serve as a novel biomarker in the prognosis of BC and
could be a regulator of KPNA4 expression.
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